847375-16-0

Basic information

• Product Name: N-[[4-[(4,10-Dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[(3,5-dihydroxyphenyl)methyl]-1-piperazinecarboxamidedihydrochloride
• Synonyms: N-[[4-[(4,10-Dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[(3,5-dihydroxyphenyl)methyl]-1-piperazinecarboxamidedihydrochloride;WAY 267464 dihydrochloride;847375-16-10;WAY 267464;WAY-267464;N-[[4-[(4,10-Dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[(3,5-dihydroxyphenyl)methyl]-1-piperazinecarboxamide
• CAS NO: 847375-16-0
• Molecular Formula: C32H35N7O4.2HCl
• Molecular Weight: 654.58668
• Product Categories: Amines;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pfizer compounds;Pharmaceuticals
• Mol File: 847375-16-0.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: Store at -20°C
• Solubility: Methanol (Slightly)
• CAS DataBase Reference: N-[[4-[(4,10-Dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[(3,5-dihydroxyphenyl)methyl]-1-piperazinecarboxamidedihydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: N-[[4-[(4,10-Dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[(3,5-dihydroxyphenyl)methyl]-1-piperazinecarboxamidedihydrochloride(847375-16-0)
• EPA Substance Registry System: N-[[4-[(4,10-Dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[(3,5-dihydroxyphenyl)methyl]-1-piperazinecarboxamidedihydrochloride(847375-16-0)

Safety Data

• Hazardous Substances Data: 847375-16-0(Hazardous Substances Data)

Usage

Description

N-[[4-[(4,10-Dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[(3,5-dihydroxyphenyl)methyl]-1-piperazinecarboxamidedihydrochloride, also known as WAY 267464, is a potent and selective non-peptide oxytocin receptor (OTR) agonist with a Ki value of 58.4 nM at the human OTR. It is a tan solid and has demonstrated anxiolytic-like effects, indicating its potential therapeutic applications.

Uses

Used in Pharmaceutical Industry:
WAY 267464 is used as a therapeutic agent for the treatment of psychosis and schizophrenia due to its potent and selective action as an oxytocin receptor agonist. Its anxiolytic-like effects make it a promising candidate for further research and development in the treatment of these mental health conditions.
Used in Research Applications:
In addition to its potential therapeutic uses, WAY 267464 is also utilized in research settings to study the role of oxytocin and its receptors in various physiological and behavioral processes. Its selectivity and potency make it a valuable tool for investigating the mechanisms of oxytocin action and its potential applications in other areas of medicine.

Upstream product

• 479234-62-3 2-methyl-4-(1-methyl-1,3a,4,5,10,10a-hexahydrobenzo[b]-pyrazolo[3,4-e][1,4]diazepine-5-carbonyl)benzonitrile 
• 1160759-52-3 4-cyano-3-methylbenzoyl chloride 
• 1542548-47-9 1-methyl-5-[(2-nitrophenyl)amino]-1H-pyrazole-4-carbaldehyde 
• 88-74-4 2-nitro-aniline 
• 117007-77-9 5-chloro-1-methyl-1H-pyrazole-4-carbaldehyde 
• 847375-10-4 4-(3,5-dihydroxy-benzyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 479234-83-8 1-methyl-1,4,5,10-tetrahydrobenzo[b]pyrazolo[3,4-e][1,4]diazepine 
• 530-62-1 1,1'-carbonyldiimidazole 
• 479234-64-5 (4-(aminomethyl)-3-methylphenyl)(1-methyl-3a,4,10,10a-tetrahydrobenzo[b]pyrazolo[3,4-e][1,4]diazepin-5(1H)-yl)methanone 
• 26153-38-8 3,5-dihydroxybenzaldehyde 
• 73831-13-7 4-cyano-3-methylbenzoic acid 

Relevant articles and documents

Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors

A previously identified, non-peptidic oxytocin (OT) receptor agonist WAY-267,464 (1) and nine novel derivatives (3, 4a-7a, 4b-7b) were synthesised and evaluated in vitro with the aim of systematically exploring hydrogen bonding interactions and ligand flexibility. All analogues were subjected to competition radioligand binding assays at human oxytocin (OT) and arginine vasopressin 1a (V1a) receptors. Physiological activity was determined using whole cell IP1 accumulation assays. Under these conditions, WAY-267,464 had higher affinity for the V1a receptor compared to the OT receptor (8.5x more selective) with poor functional selectivity (2x selective for OT receptor agonism over V1a receptor antagonism). Methylation of the resorcinol moiety (3) reversed the OT receptor pharmacological profile, removing agonist activity and inducing antagonist activity, without altering V1a receptor pharmacology. All flexible tethered derivatives removed OT receptor affinity and activity resulting in the generation of highly selective V1a receptor ligands.